Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrika S H Simonsson

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Drug Discovery Today|October 4, 2016
The implications of model-informed drug discovery and development for tuberculosisMorris Muliaditan, Geraint R Davies, Ulrika S H Simonsson, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 20, 2008
A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimensDoaa A Elsherbiny, Sara A Asimus, Mats O Karlsson, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 6, 2018
Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitorsMalte Selch Larsen, Rasmus Vestergaard Juul, Mads Kreilgaard, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2022
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drugAlan Faraj, Tom Knudsen, Shraddha Desai, et al.
Clinical Pharmacology and Therapeutics|July 5, 2003
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9Ulrika S H Simonsson, Britt Jansson, Trinh Ngoc Hai, et al.
Clinical Pharmacology and Therapeutics|February 22, 2020
Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical DevelopmentBudi O Susanto, Sebastian G Wicha, Yanmin Hu, et al.
British Journal of Clinical Pharmacology|February 16, 2011
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patientsJustin J Wilkins, Grant Langdon, Helen McIlleron, et al.
Advances in Therapy|June 21, 2023
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B PatientsAlan Faraj, Natacha Le Moan, Eduard Gorina, et al.
Scientific Reports|September 24, 2020
Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictionsAlan Faraj, Oskar Clewe, Robin J Svensson, et al.
Journal of Pharmaceutical Sciences|June 30, 2024
Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I ProteinRami Ayoun Alsoud, Natacha Le Moan, Lars Holten-Andersen, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Drug Discovery Today|October 4, 2016
The implications of model-informed drug discovery and development for tuberculosisMorris Muliaditan, Geraint R Davies, Ulrika S H Simonsson, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 20, 2008
A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimensDoaa A Elsherbiny, Sara A Asimus, Mats O Karlsson, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 6, 2018
Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitorsMalte Selch Larsen, Rasmus Vestergaard Juul, Mads Kreilgaard, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2022
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drugAlan Faraj, Tom Knudsen, Shraddha Desai, et al.
Clinical Pharmacology and Therapeutics|July 5, 2003
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9Ulrika S H Simonsson, Britt Jansson, Trinh Ngoc Hai, et al.
Clinical Pharmacology and Therapeutics|February 22, 2020
Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical DevelopmentBudi O Susanto, Sebastian G Wicha, Yanmin Hu, et al.
British Journal of Clinical Pharmacology|February 16, 2011
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patientsJustin J Wilkins, Grant Langdon, Helen McIlleron, et al.
Advances in Therapy|June 21, 2023
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B PatientsAlan Faraj, Natacha Le Moan, Eduard Gorina, et al.
Scientific Reports|September 24, 2020
Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictionsAlan Faraj, Oskar Clewe, Robin J Svensson, et al.
Journal of Pharmaceutical Sciences|June 30, 2024
Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I ProteinRami Ayoun Alsoud, Natacha Le Moan, Lars Holten-Andersen, et al.
Pageof 11